Alzamend Neuro (FRA:9ZT1) 3-Year EBITDA Growth Rate : -45.80% (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro 3-Year EBITDA Growth Rate?

Alzamend Neuro's EBITDA per Share for the three months ended in Jan. 2024 was €-0.38.

During the past 3 years, the average EBITDA Per Share Growth Rate was -45.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alzamend Neuro was -34.80% per year. The lowest was -45.80% per year. And the median was -40.30% per year.

Competitive Comparison of Alzamend Neuro's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Alzamend Neuro's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alzamend Neuro's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzamend Neuro's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Alzamend Neuro's 3-Year EBITDA Growth Rate falls into.

Alzamend Neuro 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Alzamend Neuro (FRA:9ZT1) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Alzamend Neuro 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Alzamend Neuro (FRA:9ZT1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (FRA:9ZT1) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ALZN:USA

Address

3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326

Website

https://www.alzamend.com

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Alzamend Neuro (FRA:9ZT1) Headlines

No Headlines